Head and neck squamous cell carcinoma in pregnant women by Eliassen, Anna M. et al.
ORIGINAL ARTICLE
Head and neck squamous cell carcinoma in pregnant women
Anna M. Eliassen, BS,1 Samantha J. Hauff, MD,1 Alice L. Tang, MD,1 Dafydd H. Thomas, MD, PhD,2 Jonathan B. McHugh, MD,2 Heather M. Walline, MS,3
Jay Stoerker, PhD,1† Jessica H. Maxwell, MD,1‡ Francis P. Worden, MD,4 Avraham Eisbruch, MD,5 Michael J. Czerwinski,1
Silvana M. Papagerakis, MD, PhD,1 Douglas B. Chepeha, MD,1 Carol R. Bradford, MD,1 David A. Hanauer, MD,1
Thomas E. Carey, PhD,1* Mark E. Prince, MD1*
1Department of Otolaryngology Head and Neck Surgery, The University of Michigan, Ann Arbor, Michigan, 2Department of Pathology, The University of Michigan, Ann Arbor,
Michigan, 3Department of Environmental Health Sciences and the Cancer Biology of the Program of the Program in the Biological Sciences, 4Department of Internal Medicine,
The University of Michigan, Ann Arbor, Michigan, 5Department of Radiation Oncology, The University of Michigan, Ann Arbor, Michigan.
Accepted 20 December 2011
Published online 16 March 2012 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/hed.22973
ABSTRACT: Background. The aim of this study was to investigate oral
cancer in pregnant women, a rare but therapeutically challenging
patient subset.
Methods. After institutional review board approval, an EMERSE search was
used to identify all women treated at the University of Michigan from 1998
to 2010 with head and neck squamous cell carcinoma (HNSCC) during
pregnancy. This identified 4 patients with tongue cancer. Biomarkers and
human papillomavirus (HPV) were assessed by immunohistochemistry and
multiplex PCR/mass spectrometry, respectively.
Results. Two patients responded well to therapy and are alive more
than 10 years after diagnosis; 2 patients died of disease. All tumors
overexpressed EGFR and Bcl-xL, 3 of 4 overexpressed c-Met, both
tumors that progressed overexpressed p53. All tumors were negative
for HPV, p16, estrogen receptor, progesterone receptor, and HER-2.
Conclusions. Biomarkers of aggressive tumors (high EGFR, c-Met;
high Bcl-xL-low p53) did not correlate with outcome. Additional
studies are needed to determine whether perineural invasion,
delay in diagnosis, and p53 overexpression are factors in poor
survival. VC 2012 Wiley Periodicals, Inc. Head Neck 35: 335–342,
2013
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INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is
typically considered to be a disease that predominantly
affects older men, with a male:female ratio of approxi-
mately 4:1.1 Long-term alcohol and tobacco use have
been identified as the traditional risk factors for this dis-
ease. Interestingly, recent trends have shown an increase
in the incidence of HNSCC in younger patients without
these risk factors, and there is controversy over whether
these represent a more aggressive form of cancer.2
Recently, an increased incidence of HNSCC of the tongue
in female patients has been described, which is partially
responsible for a noted fall in the male:female ratio of
patients affected by this disease.3 Therefore, although it is
still rare for a young woman of reproductive age to be
diagnosed with HNSCC, recent developments suggest an
increasing risk for this population.
When HNSCC is diagnosed in a pregnant patient, clini-
cians and patients are faced with the challenge of balanc-
ing maternal and fetal health. Although early detection
and intervention are key, it is also important to weigh the
risks of diagnostic and treatment modalities to the fetus.
The patient is faced with difficult ethical decisions, and
the clinician is often tasked with providing both optimal
treatment for the cancer and protection of the fetus.
There is a paucity of data regarding the etiology of can-
cers of the head and neck in pregnant women. The studies
that do exist are primarily case reports discussing the
challenges that clinicians face in administering treatment
that is of maximal benefit to the patient and minimal risk
to the fetus.4–7 Although the hypothesis that these tumors
are hormonally induced during pregnancy seems logical,
it has not yet been determined whether a biological pre-
disposition to HNSCC during pregnancy exists. It seems
plausible that these patients may have from a latent
human papillomavirus (HPV) that becomes active and on-
cogenic during pregnancy. However, none of the cases
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reported in the literature has been assessed for HPV sta-
tus. We report a series of cases in which pregnant women
presented with HNSCC to the University of Michigan
Department of Otolaryngology–Head and Neck Surgery
between 1998 and 2010. These patients' tumors were ana-
lyzed for biomarker expression and HPV status.
MATERIALS AND METHODS
Patient population
Permission from the institutional review board (IRB)
for human studies was granted to identify patients that
presented to the Department of Otolaryngology between
1998 and 2010 with head and neck squamous cell
carcinoma during pregnancy using the University of
Michigan's Electronic Medical Record Search Engine
(EMERSE). This query identified 4 patients. IRB
approval was also granted for use of existing patient
specimens and data.
DNA isolation
DNA were extracted from a core of formalin-fixed,
paraffin-embedded tissue taken from each pretreatment
biopsy or surgical resection specimen for HPV analysis.
The core of tissue was deparaffinized, then DNA was iso-
lated in accord with the manufacturer's protocol (QIAmp
DNA Mini Kit; Qiagen).
Immunostaining
Slides containing tissue sections from the resected
tumors were deparaffinized, rehydrated, and peroxidase-
quenched (Dako Cytomation, Glostrup, Denmark) as
described previously.8 All slides were incubated in Anti-
gen Retrieval Solution (Dako Cytomation) for 40 minutes
in 92C water bath with a buffer change midway and
allowed to cool to room temperature for 20 minutes. For
epidermal growth factor receptor (EGFR), an additional
antigen retrieval step was performed with pepsin incuba-
tion for 10 minutes at 37C. Horse serum was used for
blocking (30 minutes at room temperature). Primary anti-
bodies, prediluted EGFR/31G7, and 1:300 dilution of c-
Met/3D4 (Zymed Laboratories, South San Francisco,
CA), 1:100 dilution of p53/DO1 and 1:100 dilution of
Bcl-xL/7D9 (Lab-Vision, Fremont, CA), prediluted p16/
E6H4 (CINtec Histology, Westborough, MA), 1:200 dilu-
tion of ERa/SP1 (BioCare Medical, Concord, CA), 1:200
dilution of ERb/88 (Biogenex, San Ramon, CA), 1:50
dilution of PR/636 and 1:100 dilution of cErbB2 (HER2)
(Dako, Carpinteria, CA), were allowed to incubate over-
night at 4C. Slides were washed and secondary antibod-
ies linked to avidin/biotin peroxidase (ABC Kit; Vector
Laboratories, Burlingame, CA) were used to detect pri-
mary antibody binding. All stained slides were reviewed
and scored by an experienced pathologist using an inten-
sity scale from 1 to 4 (1 ¼ no staining; 2 ¼ weak; 3 ¼
moderately strong; 4 ¼ intense signal) and a 4-point pro-
portion-positive scale, where 1 10%; 2 ¼ 11% to 25%;
3 ¼ 26% to 50%; and 4 ¼ 51% to 100%. The intensity
and proportion were multiplied together to give an overall
immunohistochemistry (IHC) score from 0 to 16.
HPV analysis
HPV analysis from the extracted DNA from pretreat-
ment biopsies or surgical specimens was accomplished
using a sensitive and quantitative real-time polymerase
chain reaction (PCR) with primers that are specific to the
HPV-E6 region of each of the 15 most common high-risk
HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, 66, 68, 73). HPV analysis was carried out using
the Attosense multiplex PCR–mass spectrometry method
developed at the University of Michigan and licensed to
Sequenom as previously described.9
RESULTS
Case reports
Patient 1. A 26-year-old white woman with no significant
past medical history presented to our clinic with pain on
the right side of her tongue, mild dysphagia, and left-sided
otalgia. She had recently found out she was pregnant. The
patient had no history of alcohol use but had a 6-pack-
year tobacco use history. She was no longer smoking at
the time of presentation. She had no family history of can-
cer. Her exam was notable for a large, ulcerated, tender
lesion of the right lateral tongue with palpable induration
extending across the midline. Biopsy of her right lateral
tongue revealed well-differentiated invasive squamous cell
carcinoma (SCC). Preoperative CT scan revealed an irreg-
ular 3.5-cm  2.5-cm mass in the right posterior tongue
that extended inferiorly. Multiple scattered, enlarged
lymph nodes were noted bilaterally.
Following elective termination of her pregnancy, the
patient underwent bilateral selective neck dissections of
levels I through IV, subtotal glossectomy, and an antero-
lateral thigh fasciocutaneous free flap transfer. Tumor pa-
thology revealed a 5-cm well-differentiated, ulcerative
SCC with a depth of invasion of 2 cm. There was exten-
sive perineural invasion and several unilateral lymph
nodes positive for malignancy, some of which had extrac-
apsular extension. The final tumor margins were negative,
and the tumor was classified as T4aN2bM0 (Figure 1A),
with a type 3 pattern of invasion.10
The patient's postoperative recovery was complicated
by an oral–cutaneous fistula. Adjuvant platinum/pacli-
taxel chemotherapy and radiation to a dose of 60 Gray
(Gy) were recommended. After receiving 3 doses of
chemotherapy and 5.4 Gy of radiation, she was unable to
continue making her scheduled appointments.
Approximately 6 months after her surgery, the patient
presented to the emergency department with neck swelling
and was admitted for a large neck abscess. Biopsy revealed
recurrent invasive well- to moderately-differentiated SCC.
Position-emmision tomography (PET) scan demonstrated
FDG-avidity in the right neck but was negative for distant
lesions. Her recurrence was deemed unresectable, and she
was started on a palliative chemoradiation regimen. The
patient subsequently developed lung metastases and passed
away approximately 1 year after diagnosis.
Patient 2. A 33-year-old white woman presented with sore-
ness of the left tongue and a 1-month history of a neck
mass. She first noted these symptoms during her last
month of pregnancy. After delivery, she continued to
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notice increasing soreness and fullness on the left side of
her tongue as well as fullness in the left upper neck.
Notably, she had no history of tobacco or alcohol use.
Physical exam revealed a 1.7-cm  3.0 cm area of
ulceration and erythroplakia on the left lateral edge, sur-
rounded by a 0.5 cm rim of submucosal firmness. There
was no involvement of her floor of mouth or base of
tongue. Her left neck revealed a 4.0-cm  3.0-cm mass
in the submandibular region, levels I and II. Biopsy con-
firmed SCC of the tongue.
She underwent a partial glossectomy and left selective
lymph node dissection. The primary tumor was a moder-
ately differentiated, 2.3 cm mass with pushing borders.
There was no vascular invasion. She had several positive
level II lymph nodes, some with extracapsular spread. Her
tumor was classified as T2N2bM0 (Figure 1B) with a type
3 pattern of invasion.10 She received postoperative radical
external beam radiation therapy. She has returned for fol-
low up every 6 to 12 months and was free of disease at
her most recent appointment 12 years after diagnosis.
Patient 3. A 30-year-old white woman presented with a
history of intermittent soreness on her left lateral tongue,
which over several months had worsened until her pain
became persistent and interfered with her ability to eat.
She had recently found out she was pregnant. She had no
other specific complaints related to the head and neck.
She had no history of tobacco or alcohol use, and no
family history of cancer. Her exam revealed a 2 cm mu-
cosal lesion on the lateral border of her left tongue. No
apparent mass or induration was present upon palpation
of the tongue and no other masses were noted. A biopsy
confirmed SCC of her left lateral tongue with a depth of
invasion of 2 mm. MRI showed a 3 to 3.5 cm lesion of
the tongue with underlying skeletal muscle invasion with-
out evidence of cervical adenopathy.
She underwent a left hemiglossectomy, a left selective
neck dissection of levels I–III, and a tracheostomy. Pa-
thology revealed a 0.7-cm moderately-differentiated SCC
with infiltrative borders and a depth of invasion of 0.9
cm. Extensive perineural invasion was present. All cervi-
cal lymph nodes were negative. There were positive mar-
gins, requiring reoperation, after which clear margins
were obtained. The tumor was classified as T2N0M0
(Figure 1C) with a type 4 pattern of invasion.10 Postoper-
ative radiation was considered but not performed.
Approximately 4 months later, the patient noted inter-
mittent pain that became progressively worse. Imaging
was postponed until after delivery. At that time, a PET
scan showed FDG-avidity in the posterolateral tongue
extending into the base of tongue and floor of mouth.
Options for therapy included a total glossectomy and pos-
sible laryngectomy versus radiation therapy with chemo-
therapy. After discussion the latter treatment option was
chosen.
She began a platinum/paclitaxel chemotherapy regimen
followed by 70 Gy of radiation. Three months after
FIGURE 1. Hematoxylin and eosin staining of the invasive squamous cell carcinoma tissue from each of the cases. Case 1 (A), case 2 (B), case 3
(C), case 4 (D). (A–D, original magnification 200). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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completing this therapy, a PET scan revealed findings
consistent with local recurrence, a new active lesion in
the left thyroid, and multiple metabolically active lesions
in both lungs. After receiving chemotherapy with cetuxi-
mab/rapamycin, a follow-up PET scan showed a solitary
primary lung lesion that was biopsied to confirm meta-
static disease. There was no residual activity in the pri-
mary tumor site. She underwent resection of the lung
lesion, in addition to cetuximab chemotherapy. She sub-
sequently developed hoarseness and biopsies revealed
squamous cell cancer of the anterior larynx. This likely
represented a new primary as it developed remotely from
her original primary but could have been a recurrence of
her original tumor. This was treated with a laryngectomy.
At the time of surgery, the hypermetabolic lesion in the
thyroid was found to be a papillary thyroid cancer. She
developed distant metastasis, was treated with palliative
chemotherapy, and died several months later.
Patient 4. A 37-year-old white woman with a history of
premalignant changes of the right lateral tongue, includ-
ing numerous biopsies for dysplasia as well as CO2 laser
ablation for possible carcinoma in situ and leukoplakia.
She became pregnant and noted that her tumor "took off''
after the birth of her child. Shortly after she completed
her pregnancy, she noticed a mucosal tear of the glosso-
tonsillar sulcus following an episode of vomiting. One
month later, she noticed an enlarging lump in the area of
the right posterior tongue and a loose molar that was
extracted. She had no history of tobacco or alcohol use,
but her family history was positive for head and neck
cancer in her grandfather. Pathology revealed SCC on the
right lateral tongue and right retromolar trigone.
She underwent a right-sided composite resection of the
lateral tongue, floor of mouth, and lateral mandible with a
right selective neck dissection of levels I–IV. The primary
tumor was a moderately differentiated, infiltrative 5.5-cm
 4.4-cm mass. Several lymph nodes were positive, but
none exhibited extracapsular extension. This tumor was
classified as T4aN2bM0 (Figure 1D) with a type 2 pattern
of invasion.10 She completed radiation therapy approxi-
mately 3 months later. As of her last follow-up visit, she
has been free of disease 12 years from diagnosis.
Biomarker analysis
The patients' tumors had similar biomarker expression
patterns. We used biomarkers that have been previously
implicated in tumor behavior and response to therapy. All
4 tumors overexpressed epidermal growth factor recptor
FIGURE 2. Staining for EGFR (A–D), BcL-xL (E–H), c-Met (I-L), and p53 (M–P) of the squamous cell carcinoma primary tumor from each patient.
(A–H, original magnification, 200; I–P, original magnification, 400). For each biomarker patient tumor sections are presented in order, for
example panel A¼Pt 1; panel B¼Pt 2; panel C¼Pt3; and panel D¼Pt 4 and so forth for all 16 panels.
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(EGFR), all with an IHC score of 16 (Figures 2A–2D),
and Bcl-xL, with an IHC score of 12 (3,4) for patient 1
and 16 for patients 2 to 4 (Figures 2E–2H). c-Met over-
expression was observed in tumors from patients 1, 2,
and 4, with IHC scores of 16 for patients 1 and 2 and 12
(3,4) for patient 4 (Figures 2I, 2J, and 2L) but not patient
3, with an IHC score of 2 (2,1) (Figure 2K). p53 was
overexpressed in patients 1 and 3 only (Figures 2M, 2O).
All 4 of the tumors were negative for p16, estrogen re-
ceptor, progestrone receptor, and HER-2 staining (not
shown). Table 1 summarizes these biomarker results.
Etiology
Smoking and alcohol use were not a consistent factor
in the etiology of these tumors. Only 1 patient admitted
to a tobacco use history of 6 pack-years, and none admit-
ted to alcohol abuse. Only 1 patient had a family history
of head and neck cancer in a grandparent. All 4 tumors
were also negative for high-risk HPV as assessed by a
sensitive and accurate PCR mass spectroscopy assay9 as
well as by p16INK4a expression, a sensitive surrogate
marker for transcriptionally active high-risk HPV involve-
ment.11 Except for the common factor of pregnancy, the
etiology of these tumors remains a mystery.
DISCUSSION
Although HNSCC in pregnant patients is rare, it is im-
portant to understand the biology of these tumors to treat
the cancer appropriately while minimizing risk to the fe-
tus. Unfortunately, the increasing incidence of HNSCC in
young patients means that likely there will be an increas-
ing incidence of this disease in young pregnant women.
The etiology of oral squamous cancer in young women in
general, and particularly pregnant women, is perplexing.
HNSCCs are typically the result of many years of tobacco
and alcohol abuse, and have been predominantly a disease
of men in their seventh and eighth decades of life who
exhibit these social behaviors.1,2 HNSCCs are rare in
women, although with the increase in social acceptance
of cigarette smoking during the 1940s and 1950s and
active tobacco marketing campaigns for women in the
1960s and 1970s, the proportion of women with these
cancers has been slowly rising such that instead of 4:1
male-to-female ratio the current ratio is closer to 3:1 or
less.3 Nevertheless, most women that develop head and
neck cancers have long histories of exposure to tobacco
smoke and are in the later decades of life when diag-
nosed. The four pregnant patients ranged in age from 26
to 37 years. Interestingly, a review of oral cavity cancer
cases in our database revealed a total of 13 patients age
30 years and under. Remarkably, there was an inverted
sex ratio, with a 11:2 ratio of females:males, including 2
of the pregnant women, both of whom died of their dis-
ease. In contrast, the remaining 8 of 11 females are cur-
rently alive with no evidence of disease. On the other
hand, both males under 30 years died from disease within
16 months of diagnosis. Although the number of patients
age 30 years and under is small, the predominance of
females in this age group is striking, as is the better sur-
vival among the nonpregnant females in this age cate-
gory. Thus, it is important to determine the factors associ-
ated with the development of these tumors in young
females, and especially during pregnancy.
There were few clues to the differences in outcome
among the pregnant patients. One factor we considered
was whether any of these females experienced a delay in
diagnosis. In fact, patient 1 initially presented with a sore
on her tongue that was thought to be a chancre sore and
was subsequently treated with antibiotics 6 months prior
to diagnosis of malignancy. Patient 3 noted an intermit-
tent soreness that waxed and waned for 10 months before
the pain became severe enough for her to seek medical
opinion. Patient 4 had a long history of a dysplastic lesion
TABLE 1. Summary of tumor characteristics and biomarker status in the 4 patients.
Characteristic/biomarker status Patient 1 Patient 2 Patient 3 Patient 4
TNM classification T4aN2bM0 T2N2bM0 T2N0M0 T4aN2bM0
Tobacco use (pk/y) Yes (6) No No No
Pattern of invasion 3 3 4 3
Perineural invasion Yes No Yes No
Tumor differentiation Well Moderate Moderate Moderate
Extracapsular spread Yes Yes N/A No
Delay in diagnosis (months) 7 0 10 Unknown
Breaks in treatment Yes No No No
EGFR overall IHC score* 16 16 16 12 (3, 4)
Bcl-xL overall IHC score* 12 (3, 4) 16 16 16
c-MET overall IHC score* 16 16 2 (2, 1) 12 (3, 4)
ER overall IHC score* 0 0 0 0
PR overall IHC score* 0 0 0 0
HER-2 overall IHC score* 0 0 0 0
p53 overall IHC score* 12 (3, 4) 0 16 0
p16 overall IHC score* 2 (2, 1) 0 2 (2, 1) 2 (2, 1)
HPV status Negative Negative Negative Negative
Survival outcome Dead from disease Alive, no evidence
of disease
Dead from disease Alive, no evidence
of disease
Abbreviations: EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; ER, estrogen receptor; PR, progesterone receptor; HPV, human papillomavirus; N/A, not applicable.
*IHC score represents a product of a 4-point intensity scale (1 ¼ no staining; 2 ¼ weak; 3 ¼ moderately strong; 4 ¼ intense signal) and A 4-point proportion-positive scale where 1 10%, 2
¼ 11%--25%; 3 ¼ 26%--50%; 4 ¼ 51%--100%. For scores less than 16, numbers in parentheses are (intensity score, proportion score).
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that was being closely monitored and thus was diagnosed
when it seemed to accelerate growth after pregnancy. It
is unclear whether diagnosis was delayed in patient 2, as
she was initially seen and diagnosed at a different institu-
tion and complete records were not available.
Pregnancy may induce physiologic changes that can
promote neoplastic growth, such as a high metabolic
state, increased circulating growth factors, and amplified
hormonal responses mediated through the estrogen and
progesterone receptors.4,12,13 Increased expression of ER
and PR have been linked to several types of cancers.
The binding of the respective ligands to ER and PR
stimulates the proliferation of certain cell types, which
may enable DNA mutations to persist as a result of
increased cell division.14 Because these patients were
pregnant, it seemed plausible that the high levels of
estrogen and progesterone circulating during pregnancy
would contribute to oncogenesis if the malignant cells
expressed ER and/or PR. Some studies have shown an
absence of both estrogen and progesterone receptors in
SCC cells.15 However, others have reported that the ma-
jority of cases of HNSCC in males overexpress these
receptors, and the highest tumor-free survival in that
study was in the ER(þ)/PR() group.16 Our results in
the present study fail to implicate expression of either
ER-a or PR in these tumors.
HER-2 is a cell membrane–bound tyrosine kinase that
is involved in a signal transduction pathway that leads
to cell proliferation. HER-2 is an important biomarker in
breast cancer, and targeting HER-2 with herceptin is an
important component of breast cancer therapy. Recently,
some studies have explored HER-2 expression in
HNSCC17,18 but were inconclusive with respect to its
effect on prognosis. Because of the altered hormonal mi-
lieu during pregnancy, we assessed HER-2 expression in
these oral cancers as a possible biomarker. However, all
of the tumors were HER-2 negative. In the case of
breast cancers, HER-2 in combination with ER-a and
PR is used as an indicator of prognosis.19 Triple-nega-
tive breast cancers (negative for ER-a, PR, and HER-2)
are known to have a low response to drug therapy and a
worse prognosis.20 Although our patients' tumors were
all triple negative for these markers, in the absence of a
population of oral tumors that express these markers, it
is not possible to ascribe any significance to this nega-
tive finding.
The TNM classification system is used for assessing the
tumor stage of HNSCC. This system is based on primary
tumor size, regional lymph node involvement, and distant
metastases as variables for staging. Although tumor classi-
fication can help to determine prognosis, recent studies
have demonstrated that more specific histopathologic
markers play a significant role in assessing prognosis.
Among these biomarkers are perineural invasion and pat-
tern of invasion. Perineural invasion has been associated
with poor prognosis in many cancers, including HNSCC.21
Because of its association with tumor aggressiveness, it
may be 1 of the most significant tumor characteristics
influencing survival,21,22 and local recurrence.23 Patients 1
and 3 had tumors that exhibited perineural invasion. Both
of these patients experienced aggressive disease progres-
sion with multiple recurrences and death from their disease
compared with patients 2 and 4, whose tumors lacked peri-
neural invasion. Our results are consistent with perineural
invasion as an indicator of poor prognosis.
Another histopathologic biomarker that has been shown
to influence prognosis is the pattern of invasion. Pattern of
invasion (POI) is defined on a scale from type 1 to 4. A
POI type 1 is characterized by broad, pushing borders at
the invasive front; type 2 indicates a tumor with broad,
invasive fingers (separate large tumor islands); type 3 is
characterized by smaller invasive islands with more than
15 cells per island; and a POI type 4 is the most invasive
type, defined as containing invasive tumor islands smaller
than 15 cells per island.10 It has been shown that using
this histopathologic assessment over margin status is more
predictive of local disease-free and overall survival.24
Patient 4 with POI 2 is a long-term survivor, whereas only
1 of the 3 patients with more invasive POI has survived
long term without disease recurrence. Patient 3 with the
most invasive POI, type 4, experienced significant disease
progression including multiple distant metastases.
EGFR is a receptor tyrosine kinase that plays a role in
several physiologic and pathologic processes, including
apoptosis, cell cycle progression, and metastasis. It is
commonly upregulated in many cancers, especially
HNSCC.29,30 Overexpression of EGFR in oropharyngeal
cancer is inversely associated with response to induction
chemotherapy and chemoradiation therapy, and thus it is
directly associated with a poor prognosis.8 In HPV()
oropharyngeal tumors, we found that the tumors with
EGFR overexpression led to a poor prognosis, and all
HPV-negative patients in a recent organ sparing trial with
the EGFR-high phenotype died of their disease within 2
years of diagnosis.8 In the HPV(þ) cases in the same
trial, high expression of EGFR was associated with sig-
nificantly reduced disease-specific and overall survival
when compared with HPV(þ)/EGFR() cases. In spite of
the high EGFR/HPV() phenotype of all 4 tumors, 2 of
these 4 patients have enjoyed long disease-free survival.
The tumor suppressor p53 is a key component of cell
cycle regulation. In the setting of DNA damage, p53
induces cell cycle arrest and DNA repair mechanisms.
Mutations in the p53 gene have been implicated in
numerous cancers8,31 and are particularly common in
smoking-induced head and neck cancers. Wild-type p53
is expressed only transiently and, therefore, it typically
cannot be detected by immunohistology in normal cells.
Tumors that stain positive for p53 typically have a muta-
tion that allows p53 to accumulate within the cell.32
Although p53 is often mutated in oral cancers, in tumors
induced by HPV, the HPV E6 protein causes degradation
of p53, inactivating it. Thus, p53 is typically wild-type in
HPV-induced cancers, but wild-type p53 is uncommon in
HPV-negative HNSCC.
We found low or no expression of p53 in 2 of the tu-
mor specimens, consistent with wild-type p53 in these
patients; however, both patients whose tumors progressed
overexpressed p53, consistent with mutant p53. We previ-
ously had established a cell line from patient 1 and in the
course of characterizing the line we sequenced the full-
length cDNA for p53. This revealed a point mutation at
codon 157 that substitutes alanine for valine (V157A).
This is consistent with the high expression of p53 in the
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patient's tumor. Although we have not sequenced p53 in
the tumor from patient 3, the high expression indicates a
mutation in that tumor as well.
High-risk human papillomaviruses (HPVs), especially
HPV16, are now clearly implicated as etiologic factors in
many oropharyngeal and some oral cavity cancers.25,26
HPV-positive oropharyngeal cancers are also associated
with younger age at diagnosis and may arise in people
without a history of tobacco use. Furthermore, HPV-posi-
tive oropharyngeal cancers are more likely to respond to
induction chemotherapy and chemoradiation therapy.8,9
p16INK4a is a cyclin-dependent kinase inhibitor that blocks
cell cycle progression by inhibiting pRb phosphorylation.27
Whereas silencing of p16INK4a is common in many smok-
ing-related head and neck cancers,28 it is nearly always
overexpressed in HPV-positive tumors secondary to the
effect of HPV E7 oncoprotein sequestering of Rb, resulting
in release of E2F, and upregulation p16 expression. Thus,
immunohistology for p16 is often used as a marker of
HPV expression.11 Three tumors expressed only low-inten-
sity staining of p16 in a minority of cells, which is in con-
trast to the high p16 intensity and 100% tumor cell positiv-
ity that is typically observed in HPV-positive tumors. The
lack of robust p16 staining was confirmed by quantitative
real-time PCR and MALDI-TOF mass spectroscopy,9
which failed to identify any high-risk HPV in the tumor
specimens. Thus, we can eliminate HPV as a likely etiolo-
gic factor to explain the development of these tumors at
such an early age. However, the absence of HPV in all 4
of these tongue cancers arising in nonsmokers is perplex-
ing. It suggests that there is an unusual mechanism of car-
cinogenesis, or perhaps that even an inherited predisposi-
tion to cancer development is at work in these young
pregnant females. High throughput assessment of the full
cancer genome in each of these tumors may produce
insight into the carcinogenic mechanism.
Bcl-xL, an anti-apoptotic protein, is frequently over-
expressed in HNSCCs.8,32,33 Bcl-xL contributes to tumori-
genesis and treatment resistance by enabling cells that
have been damaged by carcinogens, chemotherapeutics,
or radiation to evade apoptosis. In laryngeal cancer, Bcl-
xL overexpression in combination with low expression of
wild-type p53 is associated with a decrease in response to
chemotherapy and a 16-fold increased risk of laryngec-
tomy.34 The combination of low p53 and high Bcl-xL
levels is also associated with decreased overall survival in
oropharyngeal cancer.8 Bcl-xL was overexpressed, and
p53 was low or undetectable in the pregnant patients, sug-
gesting that chemotherapy would be unlikely to add sig-
nificant benefit. Interestingly, both patients who received
chemotherapy failed to exhibit a strong benefit.
c-Met overexpression is highly correlated with tumor
invasiveness and poor overall survival in multiple cancer
types.35–37 c-Met inhibitors are being developed that
decrease metastatic growth and invasiveness in several
types of cancer.38–40 Although the data implicating c-Met
specifically in HNSCCs are sparse, the data that do exist
indicate that it is an important biomarker of poor progno-
sis and outcome in this disease. Interestingly, patient 3
had a tumor with a pattern of invasion type 4, the most
invasive type. This patient was the only of the 4 that had
an aberrant pattern of c-Met expression and did not
floridly overexpress c-Met. Clearly more work on the
association between c-Met and pattern of invasion as well
as the basis for aberrant c-Met expression in oral cancer
requires more study. Similarly, the presence of c-Met
overexpression in 3 of the 4 tumors from pregnant
patients suggests that the use of c-Met inhibitors may
have a therapeutic role in these cancers.
Although the biomarker expression pattern is similar
among all 4 patients in this study, disease progression and
survival vary greatly. Two patients, 2 and 4, had completed
their pregnancy by the time their cancer was diagnosed and
treated. It is possible that critical hormonal influences had
diminished in these patients after they completed their preg-
nancy, allowing for their better outcomes. The lack of ER
and PR expression does not exclude the possibility of other
hormonal influences impacting the growth and spread of
these cancers, given that estrogen and progesterone are not
the only hormonal variables that change dramatically during
pregnancy. For example, growth factors such as insulin-like
growth factor (IGF-1) and others that are elevated during
pregnancy could have a potent influence on epithelial cell
proliferation and tumor progression. Further study is
required to determine this possibility.
Patients 2 and 4 were able to undergo surgery followed
by radiation because they had both delivered their babies.
These 2 patients are alive and well more than 12 years af-
ter diagnosis. Patients 1 and 3 both exhibited extensive
perineural invasion, a known poor prognostic factor in
head and neck cancer, and patient 3 exhibited the most
aggressive POI. These findings prompted consideration
for adjuvant therapy.
Patient 1 had interrupted postoperative radiation and
chemotherapy and returned to complete her treatment
months after her initial therapy and after her recurrent
cancer was inoperable. It is known that prolonged treat-
ment breaks can affect ultimate local and regional control
rates and prognosis. Although this patient chose to termi-
nate her pregnancy, her inability to complete the recom-
mended course of therapy may have contributed to her
poor outcome.
Patient 3 continued her pregnancy and did not receive
radiation or chemotherapy postoperatively, as she had no
detectable nodal spread, and her only concerning risk fac-
tor was perineural invasion. It is unclear whether radia-
tion with or without chemotherapy improves local and re-
gional control rates or overall survival in patients whose
tumors exhibit perineural invasion. The NCCN guidelines
suggest considering radiation or radiation with chemother-
apy for patients whose tumors exhibit perineural invasion,
but so far there is no study that indicates that this added
therapy improves prognosis. Given the uncertainty that
additional treatment would prove to be beneficial, the
patient chose to continue her pregnancy. This patient's
cancer behaved in a very aggressive manner and the
influence of aberrant c-Met expression on her tumor biol-
ogy warrants further investigation.
Pregnancy complicates the management of patients.
Pregnancy is a state of relative immunosuppression and
increased metabolic and hormonal activity that may
affect the outcome of treatment for a wide variety of dis-
eases. Any treatment that is chosen will affect both the
mother and the fetus. The physician and mother must try
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to balance the need for treatment and the risks to the fe-
tus. Whenever possible, if equivalent therapies are avail-
able, the one with the least risk to the patient and fetus
should be selected. Treatment decisions are much more
difficult when the efficacy of the treatment is unclear
and the risks may be significant, as is the case with peri-
neural invasion in head and neck cancer. The decision to
terminate a pregnancy is generally accepted to be a per-
sonal choice. The treating physician has an obligation to
advise the mother regarding treatment options, expected
effects, and risks to the fetus. The mother ultimately
decides with the help of this advice and that from other
individuals; then she may choose to continue the preg-
nancy or not.
Physicians and expectant mothers may have a tendency
to avoid therapy or postpone full treatment until after the
completion of pregnancy for fear of causing harm to the
fetus. Ideally, treatments that are highly effective and
have little or no risk to the fetus would be available. New
treatments for HNSCC have begun to focus on the signif-
icance of molecular inhibitors that silence specific molec-
ular pathways that may decrease the severity of side
effects while increasing the response to therapy. Adminis-
tration of a more specific treatment regimen that is tai-
lored to the specific tumor biology would be more effec-
tive and decrease the toxicity to the patient. This concept
is particularly important in pregnant women to minimize
harm to the fetus while treating the cancer appropriately.
Further investigation is necessary to help determine the
exact biology of these tumors to facilitate a more specific
treatment regimen that will balance both maternal and fe-
tal health.
REFERENCES
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics,
2009. CA Cancer J Clin 2009;59:225–249.
2. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma:
increasing trends in the U.S. population ages 20–44 years. Cancer 2005;
103:1843–1849.
3. Callery CD, Spiro RH, Strong EW. Changing trends in the management of
squamous carcinoma of the tongue. Am J Surg 1984;148:449–454.
4. Layton SA, Rintoul M, Avery BS. Oral carcinoma in pregnancy. Br J Oral
Maxillofac Surg 1992;30:161–164.
5. Cheung EJ, Wagner H Jr, Botti JJ, Fedok F, Goldenberg D. Advanced oral
tongue cancer in a 22-year-old pregnant woman. Ann Otol Rhinol Laryn-
gol 2009;118:21–26.
6. Chow VL, Chan JY, Ng RW, Wei WI. Management of head and neck
tumours during pregnancy: case report and literature review. Asian J Surg
2008;31:199–203.
7. Succo G, Crosetti E, Torta R, et al. Oropharyngeal carcinoma during preg-
nancy: clinical and psycho-oncological aspects. Acta Otorhinolaryngol
Ital 2003;23:440–445.
8. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and
p53, sex, and smoking as indicators of response to therapy and survival in
oropharyngeal cancer. J Clin Oncol 2008;26:3128–3137.
9. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for
organ preservation in advanced oropharynx cancer: response and survival
positively associated with HPV16 copy number. J Clin Oncol 2008;26:
3138–3146.
10. Bryne M, Koppang HS, Lilleng R, Stene T, Bang G, Dabelsteen E. New
malignancy grading is a better prognostic indicator than Broders' grading
in oral squamous cell carcinomas. J Oral Pathol Med 1989;18:432–437.
11. Klussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 pro-
tein identifies a distinct entity of tonsillar carcinomas associated with
human papillomavirus. Am J Pathol 2003;162:747–753.
12. Shibuya H, Saiot M, Horiuchi JI, Suzuki S. Treatment of malignant head
and neck tumors during pregnancy---a report of 3 cases. Acta Oncol 1987;
26:237–238.
13. Lasaridis N, Tilaveridis I, Karakasis D. Management of a carcinoma of
the tongue during pregnancy: report of case. J Oral Maxillofac Surg 1996;
54:221–224.
14. Ostrander JH, McMahon CM, Lem S, et al. Optical redox ratio differenti-
ates breast cancer cell lines based on estrogen receptor status. Cancer Res
2010;70:4759–4766.
15. Schuller DE, Abou-Issa H, Parrish R. Estrogen and progesterone receptors
in head and neck cancer. Arch Otolaryngol 1984;110:725–727.
16. Budai B, Remenar E, Orosz Z, Szamel I, Kralovanszky J, Kasler M. Ste-
roid hormone receptors in squamous cell carcinoma of the head and neck
[in Hungarian]. Orv Hetil 1997;138:723–727.
17. Williams MD. Integration of biomarkers including molecular targeted
therapies in head and neck cancer. Head Neck Pathol 2010;4:62–69.
18. Ali MA, Gunduz M, Gunduz E, et al. Expression and mutation analysis of
her2 in head and neck squamous cell carcinoma. Cancer Invest 2010;28:
495–500.
19. Filipovic S, Kocic B, Petrovic B, Milovanovic L, Poultsidi AA. Hormone
sensitivity of primary breast carcinoma. J BUON 2010;15:255–262.
20. Kan N, Kuwata K, Mise K, Kodama H. Effective therapeutic regimens for
patients with triple-negative (ER/PgR/HER2-negative) metastatic breast
cancer [in Japanese]. Gan To Kagaku Ryoho 2010;37:1259–1264.
21. Goepfert H, Dichtel WJ, Medina JE, Lindberg RD, Luna MD. Perineural
invasion in squamous cell skin carcinoma of the head and neck. Am J Surg
1984;148:542–547.
22. Brown B, Barnes L, Mazariegos J, Taylor F, Johnson J, Wagner RL. Prog-
nostic factors in mobile tongue and floor of mouth carcinoma. Cancer
1989;64:1195–1202.
23. Hosal AS, Unal OF, Ayhan A. Possible prognostic value of histopatho-
logic parameters in patients with carcinoma of the oral tongue. Eur Arch
Otorhinolaryngol 1998;255:216–219.
24. Brandwein-Gensler M, Teixeira MS, Lewis CM, et al. Oral squamous cell
carcinoma: histologic risk assessment, but not margin status, is strongly
predictive of local disease-free and overall survival. Am J Surg Pathol
2005;29:167–178.
25. Strome SE, Savva A, Brissett AE, et al. Squamous cell carcinoma of the
tonsils: a molecular analysis of HPV associations. Clin Cancer Res 2002;
8:1093–1100.
26. Li W, Thompson CH, Cossart YE, et al. The expression of key cell cycle
markers and presence of human papillomavirus in squamous cell carci-
noma of the tonsil. Head Neck 2004;26:1–9.
27. Zhang HS, Postigo AA, Dean DC. Active transcriptional repression by the
Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta,
and contact inhibition. Cell 1999;97:53–61.
28. Wong TS, Man MW, Lam AK, Wei WI, Kwong YL, Yuen AP. The study
of p16 and p15 gene methylation in head and neck squamous cell carci-
noma and their quantitative evaluation in plasma by real-time PCR. Eur J
Cancer 2003;39:1881–1887.
29. Takes RP, Baatenburg de Jong RJ, Schuuring E, Litvinov SV, Hermans J,
Van Krieken JH. Differences in expression of oncogenes and tumor sup-
pressor genes in different sites of head and neck squamous cell. Anticancer
Res 1998;18:4793–4800.
30. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in
head and neck cancer. J Clin Oncol 2006;24:2666–2672.
31. Menendez D, Inga A, Resnick MA. Potentiating the p53 network. Discov
Med 2010;10:94–100.
32. Kumar B, Cordell KG, D'Silva N, et al. Expression of p53 and Bcl-xL as
predictive markers for larynx preservation in advanced laryngeal cancer.
Arch Otolaryngol Head Neck Surg 2008;134:363–369.
33. Sharma H, Sen S, Mathur M, Bahadur S, Singh N. Combined evaluation
of expression of telomerase, survivin, and anti-apoptotic Bcl-2 family
members in relation to loss of differentiation and apoptosis in human head
and neck cancers. Head Neck 2004;26:733–740.
34. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Sci-
ence 1998;281:1322–1326.
35. Lo Muzio L, Farina A, Rubini C, et al. Effect of c-Met expression on sur-
vival in head and neck squamous cell carcinoma. Tumour Biol 2006;27:
115–121.
36. De Herdt MJ, Baatenburg de Jong RJ. HGF and c-MET as potential
orchestrators of invasive growth in head and neck squamous cell carci-
noma. Front Biosci 2008;13:2516–2526.
37. Grugan KD, Miller CG, Yao Y, et al. Fibroblast-secreted hepatocyte
growth factor plays a functional role in esophageal squamous cell carci-
noma invasion. Proc Natl Acad Sci U S A 2010;107:11026–11031.
38. Holgren C, Dougherty U, Edwin F, et al. Sprouty-2 controls c-Met expres-
sion and metastatic potential of colon cancer cells: sprouty/c-Met upregu-
lation in human colonic adenocarcinomas. Oncogene 2010;29:5241–5253.
39. Uddin S, Hussain AR, Ahmed M, et al. Inhibition of c-MET is a potential
therapeutic strategy for treatment of diffuse large B-cell lymphoma. Lab
Invest 2010;90:1346–1356.
40. Canadas I, Rojo F, Arumi-Uria M, Rovira A, Albanell J, Arriola E. C-
MET as a new therapeutic target for the development of novel anticancer
drugs. Clin Transl Oncol 2010;12:253–260.
ELIASSEN ET AL.
342 HEAD & NECK—DOI 10.1002/HED MARCH 2013
